10X Genomics Inc (TXG)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $7.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
10X Genomics Inc (TXG) Earnings: Report Dates and Results
10X Genomics (TXG) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, 10X Genomics reported EPS of -$0.15, above the -$0.29 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TXG has an expected report date of Feb 10, 2027.
TXG Earnings Call
The latest TXG earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, TXG beat 21 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $150.67M, up 1.1% from $149.00M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.15 | -$0.29 | N/A | +48.28% | Beat | N/A | 2 | 2 up, 0 down | Nov 5, 2026 | $150.67M |
| Jun 30, 2026 | -$0.14 | -$0.23 | N/A | +39.13% | Beat | -150.0% | 3 | 2 up, 0 down | Aug 6, 2026 | $151.04M |
| Mar 31, 2026 | $0.07 | -$0.06 | -$0.09 - -$0.03 | +216.67% | Beat | N/A | 3 | 0 up, 0 down | May 7, 2026 | $150.84M |
| Dec 31, 2025 | $0.07 | -$0.04 | -$0.17 - $0.04 | +275.00% | Beat | N/A | 3 | 0 up, 0 down | Feb 12, 2026 | $166.03M |
| Sep 30, 2025 | -$0.02 | -$0.07 | -$0.07 - -$0.07 | +71.43% | Beat | N/A | 2 | 0 up, 2 down | Nov 6, 2025 | $149.00M |
| Jun 30, 2025 | $0.28 | -$0.35 | N/A | +180.00% | Beat | +2700.0% | 2 | 2 up, 0 down | Aug 7, 2025 | $172.91M |
| Mar 31, 2025 | -$0.10 | -$0.29 | -$0.33 - -$0.25 | +65.52% | Beat | N/A | 2 | 0 up, 1 down | May 8, 2025 | $154.88M |
| Dec 31, 2024 | -$0.14 | -$0.11 | -$0.30 - -$0.01 | -27.27% | Miss | N/A | 3 | 1 up, 0 down | Feb 12, 2025 | $165.02M |
| Sep 30, 2024 | -$0.02 | -$0.26 | N/A | +92.31% | Beat | N/A | 17 | 3 up, 0 down | Oct 29, 2024 | $151.65M |
| Jun 30, 2024 | $0.01 | -$0.23 | N/A | +104.35% | Beat | N/A | 17 | 1 up, 0 down | Aug 8, 2024 | $153.10M |
| Mar 31, 2024 | -$0.20 | -$0.39 | -$0.65 - -$0.30 | +48.72% | Beat | N/A | 15 | 1 up, 0 down | Apr 30, 2024 | $141.01M |
| Dec 31, 2023 | -$0.41 | -$0.36 | -$0.49 - -$0.22 | -13.89% | Miss | -295.2% | 15 | 4 up, 1 down | Feb 15, 2024 | $183.98M |
| Sep 30, 2023 | -$0.10 | -$0.04 | N/A | -150.00% | Miss | N/A | 13 | 0 up, 1 down | Nov 2, 2023 | $153.64M |
| Jun 30, 2023 | -$0.14 | -$0.05 | N/A | -180.00% | Miss | N/A | 13 | 0 up, 0 down | Aug 3, 2023 | $146.82M |
| Mar 31, 2023 | -$0.07 | -$0.16 | N/A | +56.25% | Beat | N/A | 12 | 1 up, 1 down | May 3, 2023 | $134.28M |
| Dec 31, 2022 | $0.21 | -$0.20 | N/A | +205.00% | Beat | N/A | 11 | 1 up, 0 down | Feb 15, 2023 | $156.23M |
| Sep 30, 2022 | -$0.07 | -$0.24 | N/A | +70.83% | Beat | N/A | 8 | 0 up, 0 down | Nov 2, 2022 | $131.07M |
| Jun 30, 2022 | -$0.25 | -$0.30 | -$0.48 - -$0.23 | +16.67% | Beat | N/A | 9 | 1 up, 0 down | Aug 8, 2022 | $114.61M |
| Mar 31, 2022 | -$0.14 | -$0.33 | -$0.43 - -$0.18 | +57.58% | Beat | N/A | 7 | 0 up, 0 down | May 4, 2022 | $114.50M |
| Dec 31, 2021 | -$0.16 | -$0.03 | -$0.16 - $0.01 | -433.33% | Miss | N/A | 8 | 1 up, 0 down | Feb 16, 2022 | $143.53M |
| Sep 30, 2021 | -$0.15 | -$0.21 | -$0.26 - -$0.04 | +28.57% | Beat | N/A | 9 | 0 up, 0 down | Nov 3, 2021 | $125.30M |
| Jun 30, 2021 | -$0.11 | -$0.23 | -$0.60 - -$0.05 | +52.17% | Beat | N/A | 9 | N/A | Aug 4, 2021 | $115.84M |
| Mar 31, 2021 | -$0.11 | -$0.19 | -$0.51 - -$0.10 | +42.11% | Beat | N/A | 9 | N/A | May 5, 2021 | $105.82M |
| Dec 31, 2020 | -$0.08 | -$0.07 | -$0.49 - -$0.06 | -14.29% | Miss | N/A | 8 | N/A | Feb 17, 2021 | $112.22M |
| Sep 30, 2020 | -$0.25 | -$0.31 | -$0.39 - -$0.24 | +19.35% | Beat | N/A | 7 | N/A | Nov 10, 2020 | $71.82M |
| Jun 30, 2020 | -$0.41 | -$0.49 | -$0.64 - -$0.41 | +16.33% | Beat | N/A | 6 | N/A | Aug 11, 2020 | $42.91M |
| Mar 31, 2020 | -$0.20 | -$0.13 | -$0.20 - -$0.08 | -53.85% | Miss | N/A | 5 | N/A | May 11, 2020 | $71.91M |
| Dec 31, 2019 | -$0.07 | -$0.13 | -$0.15 - -$0.07 | +46.15% | Beat | N/A | 4 | N/A | Feb 18, 2020 | $75.29M |
| Sep 30, 2019 | -$0.33 | -$0.10 | N/A | -230.00% | Miss | N/A | 2 | N/A | Nov 7, 2019 | $61.21M |
| Jun 30, 2019 | -$0.16 | -$0.11 | N/A | -45.45% | Miss | N/A | N/A | N/A | Sep 11, 2019 | $55.82M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.23, a profit after a loss of $0.35 per share the year before. It was -$0.56 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.23 | N/A |
| Dec 31, 2024 | -$0.35 | N/A |
| Dec 31, 2023 | -$0.72 | N/A |
| Dec 31, 2022 | -$0.25 | N/A |
| Dec 31, 2021 | -$0.53 | N/A |
| Dec 31, 2020 | -$0.94 | N/A |
| Dec 31, 2019 | -$0.56 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,075 | 14 | |
| 2026Q2 | Jun 30, 2026 | 7,077 | 17 | |
| 2026Q1 | Mar 31, 2026 | 6,489 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,400 | 18 | |
| 2025Q3 | Sep 30, 2025 | 6,536 | 17 | |
| 2025Q2 | Jun 30, 2025 | 6,373 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,431 | 18 | |
| 2024Q4 | Dec 31, 2024 | 7,698 | 19 |
2026Q3 Earnings Call
Opening remarks
Cassie Corneau Senior Director and Head of Investor Relations and Strategic Finance Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the third quarter ended September 30, 2026. If you have not received this news release or would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Joining the call today are Serge Saxonov, our CEO and Co-Founder, and Adam Taich, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue. With that, I will now turn the call over to Serge.
Serge Saxonov CEO and Co-Founder Thanks, Cassie, and good afternoon, everyone. Revenue for the third quarter was $151 million, up 1% year over year. The biggest highlight was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we're incredibly excited to be putting instruments in customers' hands. The rest of the business also performed well, driven by continued strength in consumables. Adam will cover the financial results and outlook in more detail. Now, stepping back, it's worth reflecting on this remarkable point in time as progress in AI is reshaping so much of the world. Many believe that AI's greatest promise is in accelerating science and advancing human health. We agree, and the key bottleneck is the data. Biology is incredibly complex. Capturing that complexity requires measuring biological systems at massive scale and high resolution. It requires measurements of molecules, cells, and tissues across vast numbers of samples, conditions, and contexts. This is precisely why we started 10x and why we have built our single-cell and spatial technologies.
Frequently Asked Questions About TXG
When is 10X Genomics's next earnings date?
10X Genomics's next earnings report is expected for Feb 10, 2027.
Did TXG beat earnings estimates last quarter?
Yes. 10X Genomics reported EPS of -$0.15 for the quarter ended Sep 30, 2026, above the -$0.29 estimate, a 48.28% surprise.
What EPS do analysts expect from TXG next quarter?
The consensus EPS estimate for 10X Genomics for the quarter ending Dec 31, 2026 is -$0.22 from 16 analysts, with estimates from -$0.33 to -$0.07.
How often does TXG beat earnings estimates?
10X Genomics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +108.59%.
TXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts